SCHEMBL21112880

SCHEMBL21112880

CO[C@@H]1[C@@H](O)[C@H](O)[C@@H](COC(=O)c2cccc(Oc3ccccc3)c2)O[C@H]1O

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.43
MAPT P10636 2/20 0.43
KMT2A Q03164 2/20 0.43
AKR1C3 P42330 1/20 0.42
POLB P06746 1/20 0.41
LGALS9 O00182 1/20 0.41
LGALS8 O00214 1/20 0.41
LGALS1 P09382 1/20 0.41
LGALS3 P17931 1/20 0.41
LGALS7; LGALS7B P47929 1/20 0.41
ALDH1A1 P00352 3/20 0.40
ERCC5 P28715 1/20 0.39
FEN1 P39748 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
TDP1 Q9NUW8 1/20 0.39
PTGS1 P23219 1/20 0.38
NPC1 O15118 1/20 0.38
TYMP P19971 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21112893 0.90 SMN1; SMN2 (0.45) MEN1MAPTKMT2AALDH1A1TDP1
SCHEMBL21113010 0.88 AKR1C3 (0.47) MEN1MAPTKMT2AAKR1C3POLB
SCHEMBL21112881 0.86 TDP1 (0.48) MEN1MAPTKMT2AAKR1C3POLB
SCHEMBL21112940 0.86 TTR (0.50) MAPTKMT2AALDH1A1TDP1NPC1
SCHEMBL21112929 0.85 MEN1 (0.40) MEN1MAPTKMT2AAKR1C3POLB
SCHEMBL21112859 0.85 SRD5A2 (0.38) MEN1KMT2AALDH1A1TDP1PTGS1
SCHEMBL22490912 0.78 CHRNB2 (0.50) MEN1KMT2APOLBALDH1A1NPC1
SCHEMBL21112887 0.77 SMN1; SMN2 (0.50) ALDH1A1TDP1PTGS1
SCHEMBL22704364 0.77 ALDH1A1 (0.48) MEN1KMT2APOLBLGALS9LGALS1
SCHEMBL19132528 0.77 ALDH1A1 (0.48) MEN1KMT2APOLBLGALS9LGALS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein SANOFI (FR) 2021-08-17 US disclosed
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN SANOFI (FR) 2019-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11090364-B2 Conjugates of a pharmaceutical agent and a moiety capable of binding to a glucose sensing protein GPR119, SLC2A8, SLC2A4 MEN1 1610/4885MAPT 3717/4885KMT2A 4658/4885
US-20190209656-A1 CONJUGATES OF A PHARMACEUTICAL AGENT AND A MOIETY CAPABLE OF BINDING TO A GLUCOSE SENSING PROTEIN GPR119, SLC2A8, SLC2A4 MEN1 1610/4885MAPT 3717/4885KMT2A 4658/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.